Improved Prostate Delineation in Prostate Hdr Brachytherapy with Trus-Ct Deformable Registration Technology: A Pilot Study with Mri Validation

Xiaofeng Yang,Peter J. Rossi,Ashesh B. Jani,Hui Mao,Zhengyang Zhou,Walter J. Curran,Tian Liu
DOI: https://doi.org/10.1002/acm2.12040
2017-01-01
Journal of Applied Clinical Medical Physics
Abstract:Accurate prostate delineation is essential to ensure proper target coverage and normal-tissue sparing in prostate HDR brachytherapy. We have developed a prostate HDR brachytherapy technology that integrates intraoperative TRUS-based prostate contour into HDR treatment planning through TRUS-CT deformable registration (TCDR) to improve prostate contour accuracy. In a perspective study of 16 patients, we investigated the clinical feasibility as well as the performance of this TCDR-based HDR approach. We compared the performance of the TCDR-based approach with the conventional CT-based HDR in terms of prostate contour accuracy using MRI as the gold standard. For all patients, the average Dice prostate volume overlap was 91.1 +/- 2.3% between the TCDR-based and the MRI-defined prostate volumes. In a subset of eight patients, inter and intro-observer reliability study was conducted among three experienced physicians (two radiation oncologists and one radiologist) for the TCDR-based HDR approach. Overall, a 10 to 40% improvement in prostate volume accuracy can be achieved with the TCDR-based approach as compared with the conventional CT-based prostate volumes. The TCDR-based prostate volumes match closely to the MRI-defined prostate volumes for all 3 observers (mean volume difference: 0.5 +/- 7.2%, 1.8 +/- 7.2%, and 3.5 +/- 5.1%); while CT-based contours overestimated prostate volumes by 10.9 +/- 28.7%, 13.7 +/- 20.1%, and 44.7 +/- 32.1%. This study has shown that the TCDR-based HDR brachytherapy is clinically feasible and can significantly improve prostate contour accuracy over the conventional CT-based prostate contour. We also demonstrated the reliability of the TCDR-based prostate delineation. This TCDR-based HDR approach has the potential to enable accurate dose planning and delivery, and potentially enhance prostate HDR treatment outcome.
What problem does this paper attempt to address?